Case Report

Carney-Stratakis Syndrome presenting as occult mediastinal paraganglioma✩

Ryan Bailey, MD, Akash Sharma, MD, Ephraim E. Parent, MD, PhD*  
Department of Radiology, Mayo Clinic, 4500 San Pablo Road, Jacksonville 32224, FL, USA

ARTICLE INFO

Article history:  
Received 21 April 2020  
Revised 9 June 2020  
Accepted 12 June 2020

Keywords:  
Carney-Stratakis Syndrome  
Paraganglioma  
FDG  
MBG

ABSTRACT

Carney-Stratakis Syndrome is defined as the combination of a paraganglioma and a gastrointestinal stromal tumor. This is recognized as unique from the more commonly known Carney Triad, which in addition to the above also has a pulmonary chondroma present. We present a case of Carney-Stratakis Syndrome which highlights the value of multimodality imaging in arriving at the diagnosis, as well as the role of genetic testing for definitively differentiating it from the more commonly recognized Carney Triad.

© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license. 
(http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

First described in 1977, the Carney Triad refers to a rare syndrome that clinically manifests as synchronous or metachronous gastrointestinal stromal tumor (GIST), pulmonary chondroma (PC), and extra-adrenal paraganglioma (PGL) [1]. However, another distinct and equally rare entity referred to as Carney-Stratakis Syndrome (CSS) has been subsequently characterized, which manifests as PGL and GIST alone [2]. Differentiating between the 2 syndromes is difficult, but has significant implications for the patient and family members; as Carney Triad is the result of sporadic postzygotic mutations, whereas CSS can be associated with a germline mutation and passed to children. Here, we present a case of CSS and discuss the pathophysiology of the syndrome.

Case report

A 38-year-old woman presented to the emergency department with worsening, nonspecific abdominal pain. As a teenager, she was diagnosed with GIST of the stomach for which she underwent resection with Roux-en-Y reconstruction. Given her oncologic history and symptoms, a 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) scan was obtained; this demonstrated recurrent GIST in the small bowel along with hepatic metastatic disease (Fig. 1). A hypermetabolic focus in the mediastinum was identified as concerning for metastatic adenopathy but no definite CT correlate was found on a concurrent diagnostic chest CT.

The patient underwent surgical resection of the recurrent small bowel tumor and hepatic metastasis with

✩ Declaration of Competing Interests: None.
* Corresponding author.
E-mail addresses: bailey.ryan2@mayo.edu (R. Bailey), sharma.akash@mayo.edu (A. Sharma), parent.ephrain@mayo.edu (E.E. Parent).
https://doi.org/10.1016/j.radcr.2020.06.029
1930-0433/© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
A pathology in keeping with GIST. A follow-up FDG PET/CT demonstrated expected postsurgical FDG uptake within the resection bed along with persistent uptake within the mediastinum; the latter focus was again reported as concerning for occult metastatic lymphadenopathy (Fig. 2). As no CT correlate had been identified for this mediastinal finding on prior contrast-enhanced CT evaluation, an electrocardiogram (EKG)-gated contrast-enhanced chest CT was obtained. This revealed an enhancing lesion anterior to the left mainstem bronchus and was biopsy proven to be a paraganglioma. Whole body molecular imaging with $^{[123]}$-metaiodobenzylguanidine (MIBG) was subsequently performed with no scintigraphic evidence for metastatic disease from the paraganglioma. Given the concurrent presence of these 2 malignancies, genetic analysis was performed demonstrating a mutation within the gene encoding succinate dehydrogenase subunit B (SDH-B), in keeping with CSS.

**Discussion**

Twenty-five years after Carney first described his eponymous triad, Stratakis and Carney described a separate syndrome of PGL and GIST without the presence of PC [2]. Termined the CSS this disorder has been described in only a handful of patients around the world with the largest study to date including only 5 affected families. Both Carney Triad and CSS are associated with SDH mutations; however, while Carney Triad has been found to be associated with postzygotic epigenetic SDH-C mutations [3,4], familial SDH germline mutations are responsible for CSS. It has been suggested that the disorder is greatly underdiagnosed and may be more common than the Carney triad [5,6].

GISTs are integral to the diagnosis of CSS and Carney Triad, and are mesenchymal tumors found in the stomach and small intestine. While most GIST arise from a mutation in KIT or platelet-derived growth factor receptor alpha, about 7.5% of GISTs have mutations in SDH genes, including those arising as part of the Carney-Stratakis dyad [7]. However, patients with Carney triad have GIST typically caused by mutation in KIT or platelet-derived growth factor receptor alpha and no definite link to SDH mutations [5,8]. Distinguishing Carney Triad from CSS on the basis of clinical findings alone is difficult, as many patients with Carney Triad present with only 2 of the 3 components and their occurrence is often metachronous. Likewise, both syndromes reflect a chronic condition with outcomes largely dependent on the behavior of GIST metastases, regardless of the conventional risk category [9,10]. Despite these similarities, distinguishing patients with CSS from those with Carney Triad has significant implications for the patient and family. While there is a low penetrance of cancer and syndromes in the families of patients with CSS [11,12], there are no reported familial cases of Carney triad. Germline mutations of SDH, as seen in CSS, result in autosomal dominant inherited cancer syndromes with variable clinical presentations and metastatic potential [13]. Therefore, genetic testing provides a definitive diagnosis of CSS and should be utilized for
early detection of the syndrome in immediate family members and descendants [1,5,14]. When identifying paragangliomas, anatomic imaging has an almost 100% sensitivity for adrenal chromaffin tumors, but has a lower accuracy for extra-adrenal disease and in complex disease scenarios, such as CSS [15]. Molecular imaging of paragangliomas with [68Ga]-DOTA-(Tyr³)-octreotate (DOTATATE) and MIBG have shown high specificity and sensitivity in identifying sites of primary disease and metastatic spread. While a complete discussion of the genetics that drive paraganglioma development are beyond the scope of this case report, it should be noted that paraganglioma that follow the pseudohypoxic tricarboxylic acid cycle (TCA) cycle pathway, which include those with familial SDH mutations, overexpress the somatostatin receptor, particularly the somatostatin receptor (SSTR) type 2 (SSTR2). DOTATATE targets the SSTR2 receptor with high affinity and affords a near perfect detection rate for primary and metastatic paragangliomas [16]. MIBG continues to have a role in identifying paragangliomas that follow the Kinase signaling pathway, which are found in a separate subset of genetic subtypes including MEN type 2 [17]. While the mediastinal paraganglioma in this case underwent acceptable molecular imaging with MIBG, paragangliomas expressing the SDH mutation are known to have the highest expression of somatostatin receptors, especially SSTR2, and could preferentially have been evaluated with DOTATATE.

Conclusions

This case is noteworthy, not only for the rarity of the diagnosis, but also in its illustration of how a combination of metabolic and focused diagnostic imaging strategies can be used to make subtle diagnoses. Whereas it would be easy to disregard the mediastinal FDG uptake in this case without a correlate on the nongated CT images, a more careful approach using the knowledge of this syndromic association can help identify the potential for malignancy, and lead to further evaluation. In this case, this quest for a definitive answer improved diagnostic outcomes not only for the patient in question, but also potentially for immediate family members or descendants who may share the diagnosis.

References

[1] Carney JA, Sheps SG, Go VL, Gordon H. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 1977;296(26):1517–18.
[2] Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney Triad. Am J Med Genet 2002;108(2):132–9.
[3] Killian JK, Miettinen M, Walker RL, Wang Y, Zhu YJ, Waterfall JJ, et al. Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci Transl Med 2014;6(268):268ra177.

[4] Haller F, Moskalev EA, Fauz FR, Barthelmes S, Wiemann S, Bieg M, et al. Abluent DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 2014;21(4):567–77.

[5] Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney Triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis Syndrome): molecular genetics and clinical implications. J Intern Med 2009;266(1):43–52.

[6] Settas N, Fauz FR, Stratakis CA. Succinate dehydrogenase (SDH) deficiency, Carney Triad and the epigenome. Mol Cell Endocrinol 2018;469:107–11.

[7] Pasini B, McWhinney SR, Bei T, Mayakhina L, Stergiopoulos S, Muchow M, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008;16(1):79–88.

[8] Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016;2(7):922–8.

[9] Carney JA. Carney triad. Front Horm Res 2013;41:92–110.

[10] Mason EF, Hornick JL. Conventional risk stratification fails to predict progression of succinate dehydrogenase-deficient gastrointestinal stromal tumors: a clinicopathologic study of 76 cases. Am J Surg Pathol 2016;40(12):1616–21.

[11] Benn DE, Gimenex-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006;91(3):827–36.

[12] Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudij L, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 2011;96(9):E1472–6.

[13] Tufton N, Ghelani R, Srinangalingam U, Kumar AV, Drake WM, Iacovazzo D, et al. SDHA mutated paragangliomas may be at high risk of metastasis. Endocr Relat Cancer 2017;24(7):L43–9.

[14] Alrashdi I, Bano G, Maher ER, Hodgson SV. Carney triad versus Carney-Stratakis syndrome: two cases which illustrate the difficulty in distinguishing between these conditions in individual patients. Fam Cancer 2010;9(3):443–7.

[15] Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [(68)Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 2015;21(17):3888–95.

[16] Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FL, et al. PET/CT comparing [(68)Ga]-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2016;43(10):1784–91.

[17] Crona J, Taieb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev 2017;38(6):489–515.